choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Moxatag

Moxatag Newsletter
  • Vernalis PLC: FDA Issues Complete Response Letter on CCP-08 NDA 07 Aug 2017 06:20 GMT

    … Food and Drug Administration (FDA) has issued … stage pharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • FDA knocks-back second Vernalis cough and cold treatment 16 Aug 2017 11:59 GMT

    … April the Food and Drug Administration (FDA) sent a complete … it already has a medicine on the US market … including Moxatag (amoxicillin extended release) indicated for the treatment of … and frovatriptan for the acute treatment of migraines. Please enable …

  • FDA Issues Complete Response Letter on CCP-08 NDA 07 Aug 2017 06:31 GMT

    … Food and Drug Administration (FDA) has issued … stage pharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration 26 Apr 2017 06:07 GMT

    treatment of the first patient in a Servier sponsored trialpharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • Vernalis PLC: FDA Issues a Complete Response Letter on CCP-07 NDA 21 Apr 2017 06:22 GMT

    … Food and Drug Administration (FDA) has issued … stage pharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc 14 Feb 2017 07:23 GMT

    … a US-based biotechnology company focused on … stage pharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc 14 Feb 2017 07:05 GMT

    … a US-based biotechnology company focused on … stage pharmaceutical company with significant expertise in drugtreatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • Vernalis PLC: FDA accepts CCP-08 NDA for full review 21 Dec 2016 07:03 GMT

    … have to swallow a pill. Tris' … stage pharmaceutical company with significant expertise in drug development … treatment of tonsillitis and/or pharyngitis secondary to StreptococcusMoxatag®, frovatriptan and other products by consumers and medical

  • Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program 06 Jan 2016 07:34 GMT

    … a U.S.-based biotechnology company. At the time … commercial stage pharmaceutical company with significant expertise in drug development. … prescription cough cold market; MOXATAG®, a once-a-day … to Streptococcus pyogenes; and frovatriptan for the acute treatment

Satisfied with the content?

Continue to create your account.